

Giuseppe Danilo Norata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5306139/publications.pdf>

Version: 2024-02-01

179
papers

10,154
citations

26630

56
h-index

39675

94
g-index

182
all docs

182
docs citations

182
times ranked

16820
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	1.8	5
2	Defective lipid signalling caused by mutations in <i>PIK3C2B</i> underlies focal epilepsy. <i>Brain</i> , 2022, 145, 2313-2331.	7.6	10
3	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. <i>FASEB Journal</i> , 2022, 36, e22107.	0.5	16
4	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	3.8	9
5	Interleukin 1 receptor 8 deficiency does not impact atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2022, 0, .	3.4	0
6	Loss of voltage-gated hydrogen channel 1 expression reveals heterogeneous metabolic adaptation to intracellular acidification by T cells. <i>JCI Insight</i> , 2022, 7, .	5.0	7
7	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 839-856.	2.4	6
8	Monocarboxylate transporter 1 deficiency impacts CD8+ T lymphocytes proliferation and recruitment to adipose tissue during obesity. <i>IScience</i> , 2022, 25, 104435.	4.1	12
9	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. <i>Cardiovascular Research</i> , 2021, 117, 2069-2082.	3.8	31
10	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. <i>Cardiovascular Research</i> , 2021, 117, 29-42.	3.8	164
11	Insights from ORION studies: focus on inclisiran safety. <i>Cardiovascular Research</i> , 2021, 117, 24-26.	3.8	6
12	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100918.	6.4	13
13	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	3.8	33
14	Dyslipidaemia and regulatory T-cell migration: an immunometabolic connection?. <i>Cardiovascular Research</i> , 2021, 117, 1235-1237.	3.8	1
15	Metabolomics, Lipidomics, and Immunometabolism. <i>Methods in Molecular Biology</i> , 2021, 2285, 319-328.	0.9	7
16	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> , 2021, 13, 304.	4.1	16
17	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. <i>Immunometabolism</i> , 2021, 3, e210014.	1.6	16
18	Novel acquisitions in cell immunometabolism. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100945.	6.4	0

#	ARTICLE	IF	CITATIONS
19	Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. <i>Cell Metabolism</i> , 2021, 33, 300-318.e12.	16.2	35
20	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	4.1	23
21	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 701275.	4.8	7
22	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3078-3090.	2.2	50
23	DDASSQ: An open-source, multiple peptide sequencing strategy for label free quantification based on an OpenMS pipeline in the KNIME analytics platform. <i>Proteomics</i> , 2021, 21, e2000319.	2.2	10
24	In silico drug repurposing in COVID-19: A network-based analysis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111954.	5.6	17
25	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 79.	4.8	23
26	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	2.5	7
27	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
28	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. <i>European Heart Journal</i> , 2020, 41, 2487-2497.	2.2	50
29	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. <i>Cancer Research</i> , 2020, 80, 3906-3919.	0.9	36
30	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2289.	2.4	19
31	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	4.8	26
32	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	4.8	41
33	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	1.8	8
34	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
35	Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. <i>PLoS ONE</i> , 2020, 15, e0240669.	2.5	15
36	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019, 40, 357-368.	2.2	124

#	ARTICLE	IF	CITATIONS
37	Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases. <i>Cardiovascular Research</i> , 2019, 116, 256-257.	3.8	0
38	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	3.8	63
39	Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 104-115.	8.7	34
40	Fuel for thought: immunometabolism is a paradigm shift in understanding immunity in cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, 1383-1384.	3.8	4
41	Immunometabolic function of cholesterol in cardiovascular disease and beyond. <i>Cardiovascular Research</i> , 2019, 115, 1393-1407.	3.8	52
42	Cholesterol metabolism, pancreatic β -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	3.8	76
43	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. <i>Current Diabetes Reports</i> , 2019, 19, 21.	4.2	28
44	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 571.	4.8	43
45	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. <i>Cardiovascular Research</i> , 2019, 115, 1861-1872.	3.8	36
46	The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-11.	3.0	79
47	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	2.7	18
48	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	2.4	65
49	Zc3h10 is a novel mitochondrial regulator. <i>EMBO Reports</i> , 2018, 19, .	4.5	23
50	Trained immunity and cardiovascular disease: is it time for translation to humans?. <i>Cardiovascular Research</i> , 2018, 114, e41-e42.	3.8	7
51	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 12.	4.8	67
52	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. <i>Pharmacological Research</i> , 2018, 130, 1-11.	7.1	22
53	Disease trends over time and CD4 + CCR5 + T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 53-63.	2.6	31
54	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration. <i>PLoS ONE</i> , 2018, 13, e0191172.	2.5	51

#	ARTICLE	IF	CITATIONS
55	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nature Communications</i> , 2018, 9, 3083.	12.8	95
56	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 379-395.	2.6	52
57	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 + T Cell Differentiation via PI3K p110 β -Akt-Mediated Signals. <i>Cell Metabolism</i> , 2017, 25, 593-609.	16.2	124
58	A past and present overview of macrophage metabolism and functional outcomes. <i>Clinical Science</i> , 2017, 131, 1329-1342.	4.3	87
59	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	5.4	105
60	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 106, 55-67.	1.9	45
61	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. <i>Molecular Therapy</i> , 2017, 25, 2435-2437.	8.2	1
62	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
63	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1870-1877.	1.8	55
64	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. <i>Immunity</i> , 2017, 47, 875-889.e10.	14.3	181
65	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 343-351.	2.3	14
66	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
67	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0162473.	2.5	41
68	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1182-1190.	3.8	32
69	Circulating CD14+ and CD14 ^{high} CD16 ⁺ classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. <i>Atherosclerosis</i> , 2016, 255, 171-178.	0.8	32
70	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105
71	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. <i>International Journal of Cardiology</i> , 2016, 223, 43-45.	1.7	2
72	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 194-205.	1.8	74

#	ARTICLE	IF	CITATIONS
73	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1165-1173.	1.8	33
74	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 141-153.	2.6	42
75	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. <i>Atherosclerosis</i> , 2016, 246, 208-213.	0.8	78
76	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015, 114, 186-197.	3.4	21
77	Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid Atherosclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-15.	3.0	135
78	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. <i>PLoS ONE</i> , 2015, 10, e0122414.	2.5	10
79	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Experimental Medicine</i> , 2015, 212, 905-925.	8.5	128
80	Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. <i>Journal of Internal Medicine</i> , 2015, 277, 478-487.	6.0	49
81	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. <i>Atherosclerosis</i> , 2015, 239, 209-217.	0.8	17
82	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015, 220, 1025-1029.	1.9	20
83	Carotid Intima-Media Thickness Progression and Risk of Vascular Events in People With Diabetes: Results From the PROG-IMT Collaboration. <i>Diabetes Care</i> , 2015, 38, 1921-1929.	8.6	67
84	PI3K-C2 β is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. <i>Nature Communications</i> , 2015, 6, 7400.	12.8	155
85	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
86	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates <i>BCAR1</i> and Suggests a Causal Variant. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 696-706.	5.1	17
87	The Cellular and Molecular Basis of Translational Immunometabolism. <i>Immunity</i> , 2015, 43, 421-434.	14.3	161
88	Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 455-482.	1.8	37
89	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	1.8	145
90	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	1.9	94

#	ARTICLE	IF	CITATIONS
91	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	3.8	236
92	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	16.2	92
93	The Missing Link Between High-Density Lipoprotein Cholesterol and Inflammatory Response in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2747-2748.	2.8	0
94	The CD1d-Natural Killer T Cell Axis in Atherosclerosis. <i>Journal of Innate Immunity</i> , 2014, 6, 3-12.	3.8	20
95	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
96	Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. <i>Atherosclerosis</i> , 2014, 234, 381-382.	0.8	3
97	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014, 88, 107-113.	7.1	48
98	Targeting PCSK9 for Hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 273-293.	9.4	96
99	Novel concepts in HDL pharmacology. <i>Cardiovascular Research</i> , 2014, 103, 423-428.	3.8	31
100	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	4.8	12
101	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 518-523.	2.6	31
102	New therapeutic principles for Familial Hypercholesterolemia. <i>Clinical Biochemistry</i> , 2014, 47, 756.	1.9	0
103	PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014, 62, 103-111.	2.1	30
104	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 751-759.	2.6	39
105	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr ^{-/-} mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 796-802.	3.4	87
106	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	1.9	23
107	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013, 34, 1783-1789.	2.2	90
108	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	1.7	15

#	ARTICLE	IF	CITATIONS
109	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. <i>Cardiology</i> , 2013, 124, 116-125.	1.4	509
110	Gene silencing approaches for the management of dyslipidaemia. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 198-205.	8.7	29
111	MicroRNAs and lipoproteins: A connection beyond atherosclerosis?. <i>Atherosclerosis</i> , 2013, 227, 209-215.	0.8	36
112	Identification of seven loci affecting mean telomere length and their association with disease. <i>Nature Genetics</i> , 2013, 45, 422-427.	21.4	808
113	Pharmacogenetics in Cardiovascular Disorders: An Update on the Principal Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 79-85.	2.2	2
114	-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease. <i>PLoS ONE</i> , 2013, 8, e60089.	2.5	11
115	LOX-1, OxLDL, and Atherosclerosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	3.0	548
116	Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	89
117	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. <i>Journal of Internal Medicine</i> , 2013, 274, 252-262.	6.0	68
118	The Thyroid Receptor Modulator KB3495 Reduces Atherosclerosis Independently of Total Cholesterol in the Circulation in ApoE Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e78534.	2.5	7
119	Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis. <i>PLoS ONE</i> , 2013, 8, e53808.	2.5	23
120	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. <i>Current Pharmaceutical Design</i> , 2013, 19, 3841-3857.	1.9	27
121	High density lipoproteins and atherosclerosis: emerging aspects. <i>Journal of Geriatric Cardiology</i> , 2013, 9, 401-407.	0.2	20
122	Antigen-Dependent and Antigen-Independent Pathways Modulate CD4 ⁺ CD28 ^{null} T-Cells During Atherosclerosis. <i>Circulation Research</i> , 2012, 111, e48-9; author reply e50-1.	4.5	7
123	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 696-703.	2.4	69
124	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e58.	5.1	11
125	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	1.7	2
126	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012, 1, 27-41.	3.7	114

#	ARTICLE	IF	CITATIONS
127	Microrna 143â€“145 Deficiency Impairs Vascular Function. International Journal of Immunopathology and Pharmacology, 2012, 25, 467-474.	2.1	29
128	Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis, 2012, 220, 11-21.	0.8	158
129	Leonurine: A new comer in the natural compounds affecting atherosclerosis. Atherosclerosis, 2012, 224, 37-38.	0.8	9
130	HDL and adaptive immunity: A tale of lipid rafts. Atherosclerosis, 2012, 225, 34-35.	0.8	21
131	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 927-935.	3.8	9
132	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. PLoS ONE, 2012, 7, e31086.	2.5	21
133	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. Food and Nutrition Sciences (Print), 2012, 03, 274-280.	0.4	1
134	Pentraxins and Atherosclerosis. , 2012, , 219-237.		0
135	Novel biotinylated bile acid amphiphiles: Micellar aggregates formation and interaction with hepatocytes. Organic and Biomolecular Chemistry, 2011, 9, 2899.	2.8	0
136	Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structureâ€“function relation to therapeutic inhibition. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 835-843.	2.6	95
137	Therapy and clinical trials. Current Opinion in Lipidology, 2011, 22, 324-325.	2.7	1
138	HDLs, immunity, and atherosclerosis. Current Opinion in Lipidology, 2011, 22, 410-416.	2.7	41
139	Lecithin:cholesterol acyltransferase and vascular disease. Clinical Lipidology, 2010, 5, 13-15.	0.4	0
140	The Long Pentraxin PTX3: A Modulator of the Immunoinflammatory Response in Atherosclerosis and Cardiovascular Diseases. Trends in Cardiovascular Medicine, 2010, 20, 35-40.	4.9	136
141	Circulating CD4 ⁺ CD25 ^{hi} CD127 ^{lo} Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1832-1841.	2.4	125
142	Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 56-63.	2.6	29
143	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. American Heart Journal, 2010, 159, 730-736.e2.	2.7	37
144	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis, 2010, 208, 177-182.	0.8	74

#	ARTICLE	IF	CITATIONS
145	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. <i>Atherosclerosis</i> , 2010, 210, 78-87.	0.8	48
146	The androgen derivative 5 α -androstane-3 β ,17 β -diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. <i>Atherosclerosis</i> , 2010, 212, 100-106.	0.8	37
147	Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis. <i>Circulation</i> , 2009, 120, 699-708.	1.6	252
148	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 129-134.	2.6	94
149	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. <i>Atherosclerosis</i> , 2009, 206, 556-562.	0.8	69
150	Cholesterol Absorption Inhibitors. , 2009, , 288-297.		0
151	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	2.4	137
152	Response to Letter by Kotani et al. <i>Stroke</i> , 2008, 39, .	2.0	0
153	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 267-278.	2.3	21
154	Leptin:Adiponectin Ratio Is an Independent Predictor of Intima Media Thickness of the Common Carotid Artery. <i>Stroke</i> , 2007, 38, 2844-2846.	2.0	164
155	Plasma resistin levels correlate with determinants of the metabolic syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 279-284.	3.7	176
156	Triglyceride-Rich Lipoproteins From Normotriglyceridemic Subjects and Hyperlipidemic Patients Differently Affect Endothelial Cell Activation and Gene Expression Patterns. <i>Circulation Research</i> , 2007, 100, e81.	4.5	9
157	Triglyceride-rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. <i>Future Lipidology</i> , 2007, 2, 119-122.	0.5	0
158	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 543-548.	2.1	5
159	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.8	131
160	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. <i>Atherosclerosis</i> , 2007, 193, 321-327.	0.8	122
161	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 21-31.	2.2	2
162	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. <i>International Congress Series</i> , 2007, 1303, 121-128.	0.2	1

#	ARTICLE	IF	CITATIONS
163	Effect of the ?420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007, 262, 104-112.	6.0	60
164	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 484-494.	1.9	55
165	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	2.6	75
166	HDL and endothelial function: from molecular mechanisms to clinical observations. <i>Future Lipidology</i> , 2006, 1, 343-355.	0.5	3
167	Dihydrotestosterone Decreases Tumor Necrosis Factor- α and Lipopolysaccharide-Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 546-554.	3.6	139
168	Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness. <i>Stroke</i> , 2006, 37, 1558-1561.	2.0	48
169	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006, 18, 209-13.	4.0	11
170	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. <i>Journal of Internal Medicine</i> , 2005, 258, 21-27.	6.0	74
171	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. <i>Circulation</i> , 2005, 111, 2805-2811.	1.6	84
172	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , 2005, 1, 119-129.	2.3	63
173	HDL Induces Cyclooxygenase-2 Expression and Prostacyclin Release in Human Endothelial Cells Via a p38 MAPK/CRE-Dependent Pathway: Effects on COX-2/PGI-Synthase Coupling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 871-877.	2.4	92
174	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	2.5	53
175	Matrix metalloproteinase-26 (Matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 94, 661-670.	1.4	29
176	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor- α in human endothelial cells. <i>Matrix Biology</i> , 2004, 22, 557-560.	3.6	32
177	Lipid lowering activity of drugs affecting cholesterol absorption. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 42-51.	2.6	14
178	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	3.8	59
179	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003, 12, 73-8.	4.0	13